Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Tirzepatide's Zepbound label reports similar figures, with nausea at 31% and constipation at 17% at the 15 mg dose in SURMOUNT-1 [2][4]
Diabetes GLP-1s perform better but still leak demand: Diabetes-indicated GLP-1s show higher retention (24% at one year) and face fewer access hurdles due to broader coverage and disease framing, yet 76% of demand remains unmet
Insulin-like growth factors in the fed and fasted states
Retatrutide is also being investigated for its impact on cardiovascular risk factors and other metabolic health markers, including its potential role in the prevention or management of cardiovascular disease
US$ 29.12
US$ 21.03
US$ 25.65
US$ 26.10
US$ 25.32
US$ 24.55
US$ 23.53
